CN104042567A - Ampelopsin nano-micelle and application thereof - Google Patents
Ampelopsin nano-micelle and application thereof Download PDFInfo
- Publication number
- CN104042567A CN104042567A CN201410249243.9A CN201410249243A CN104042567A CN 104042567 A CN104042567 A CN 104042567A CN 201410249243 A CN201410249243 A CN 201410249243A CN 104042567 A CN104042567 A CN 104042567A
- Authority
- CN
- China
- Prior art keywords
- ampelopsin
- nano
- micelle
- carrier
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 196
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000000693 micelle Substances 0.000 title claims abstract description 63
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims abstract description 8
- 229920001992 poloxamer 407 Polymers 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 239000010409 thin film Substances 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 230000036571 hydration Effects 0.000 claims description 8
- 238000006703 hydration reaction Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 5
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 5
- 201000001514 prostate carcinoma Diseases 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- -1 vitamin E succinic acid ester Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000012528 membrane Substances 0.000 description 6
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000219099 Parthenocissus quinquefolia Species 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an ampelopsin nano-micelle and application thereof. The ampelopsin nano-micelle is prepared from a carrier and ampelopsin, wherein the carrier is a mixture of pluronic F127 and D-alpha-tocopheryl polyethylene glycol 1000 succinate; the feeding mass ratio of the ampelopsin to the carrier is (1:10)-(1:30); the feeding mass ratio of the pluronic F127 to the D-alpha-tocopheryl polyethylene glycol 1000 succinate in the carrier is (1:3)-(1:10). The ampelopsin nano-micelle can be used for remarkably improving the solubility of ampelopsin, has a higher encapsulation efficiency and a certain sustained-release effect, can be applied to injection, and can be used for remarkably improving the treatment effect when being used for treating patients with prostatic cancer.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of ampelopsin nano-micelle and application thereof.
Background technology
Ampelopsin has another name called dihydromyricetin, and this compound is separated obtaining the leaf of A. Meliaefolia A.Meliaefolia first in 1940 from Vitaceae ampelopsis fujian tea with Kubota by Kotake, called after ampelopsin.Ampelopsin has been proved to be antitumor, antioxidation, blood fat reducing, antiinflammatory, the effect such as antibacterial, but because its dissolubility is little, and may be through bacterial action and by metabolism in intestinal, so oral administration bioavailability is low.Separately, because dissolubility in its water is little, be unfavorable for making drug administration by injection form.These are all to affect the obstacle that it is applied clinically, and the Related product that yet there are no ampelopsin monomer is applied to clinical.Although there is bibliographical information (Ruan LP, Yu BY, et.al.Improving thesolubility of ampelopsin by solid dispersions and inclusion complexes.Journal ofPharmaceutical andBiomedical Analysis.2005,38 (3): 457-64) adopt the preparation techniques such as solid dispersions technique, cyclodextrin inclusion technique to improve the dissolubility of ampelopsin, but these methods exist complicated process of preparation, cost is high and can only solely improve dissolubility, and can not reach slow release and the object of injecting purposes.And adopt the reagent such as surfactant, ethanol, dimethyl sulfoxide to increase dissolubility, there is again the shortcoming that toxicity or zest are large.
Due to the existence of these problems, therefore, ampelopsin water solublity a kind ofly can be improved in the urgent need to developing in this area, can delay drug release again, extends biological half-life, improves a kind of novel ampelopsin induction system of curative effect.
Summary of the invention
The object of this invention is to provide a kind of ampelopsin nano-micelle, it can improve ampelopsin water solublity, can delay drug release again, extends biological half-life, and can improve curative effect.
Ampelopsin nano-micelle provided by the present invention, is prepared from by carrier and ampelopsin; Described carrier is the mixture of pluronic F127 and polyethylene glycol 1000 vitamin E succinate.
In above-mentioned ampelopsin nano-micelle, the mass ratio that feeds intake of ampelopsin and carrier is 1: 10 to 1: 30 (1: 10-30), is preferably 1: 20.
In above-mentioned carrier, the mass ratio that feeds intake of described pluronic F127 and polyethylene glycol 1000 vitamin E succinate is 1: 3 to 1: 10 (1: 3-10), be preferably 1: 8, described polyethylene glycol 1000 vitamin E succinate, is called for short TPGS
1000.
The preparation method of above-mentioned ampelopsin nano-micelle, comprise the steps: described ampelopsin and described carrier to be placed in container, add wherein again methanol, described paclitaxel and described carrier are dissolved in described methanol, remove again methanol and make the mixture of described paclitaxel and described carrier by rotary evaporation, form thin film (refinement explanation possibly here: " mixture is how can form thin film on container inner wall ") on described container inner wall, in described container, add purified water again, formed thin film on chamber wall is carried out to hydration process, obtain hydration process product, obtain described ampelopsin nano-micelle, the described methanol step of removing again can be by Rotary Evaporators vacuum, to remove methanol under preference temperature, or other this area routine is removed methanol measure and all can.
In the preparation method of above-mentioned ampelopsin nano-micelle, the method for described hydration process is for being equipped with container jolting 30min at 37 ℃ of described thin film and purified water, and described jolting can be ultrasound treatment patterns, or other this area conventional measure all can.
In the preparation method of above-mentioned ampelopsin nano-micelle, after described hydration process, hydration process product can also be carried out to the step of 0.1 μ m aperture membrane filtration.
The mean diameter of above-mentioned ampelopsin nano-micelle is 22.8 ± 0.5nm.
The polydispersity coefficient of the particle diameter of above-mentioned ampelopsin nano-micelle is all less than 0.2.
The Zeta potential of above-mentioned ampelopsin nano-micelle is-20.73mV.
In above-mentioned ampelopsin nano-micelle, the content of ampelopsin is 3.27 ± 0.12mg/ml.
The application of above-mentioned arbitrary described ampelopsin nano-micelle in the medicine that suppresses tumor in preparation also belongs to protection scope of the present invention.
In above-mentioned application, described inhibition tumor is for suppressing the propagation of tumor and/or the survival of inhibition tumor cell;
In above-mentioned application, the propagation that the propagation of described inhibition tumor is inhibition tumor cell and/or inhibition tumor sphere volume increase and/or promote disintegrating of tumor ball;
In above-mentioned application, described tumor is carcinoma of prostate; Described prostatic cell is prostate gland cancer cell PC-3, prostate gland cancer cell DU-145.
Beneficial effect of the present invention:
1) ampelopsin nano-micelle of the present invention, has improved 16 times of left and right by ampelopsin dissolubility in water, makes it can meet the requirement of daily drug administration by injection dosage.And preparation can cumulative release in 12h more than 80%, in the time of the release of prolong drug, can guarantee again the release completely of medicine, improve the therapeutic effect of medicine.
2) ampelopsin nano-micelle of the present invention, adopts two kinds of carrier materials to mix and uses, and improves envelop rate and the stability of medicine, and the drug resistance that can overcome medicine produces the outer row that can reduce again medicine in cell, gives full play to the therapeutical effect of medicine.
3) preparation of the present invention has good auxiliary therapeutic action to the disease of the serious harm human healths such as tumor, and particularly the therapeutic effect of carcinoma of prostate is obvious.
Accompanying drawing explanation
Fig. 1 describes ampelopsin nano-micelle transmission electron microscope scintigram.
Fig. 2 is the figure that describes the drug-eluting curve of ampelopsin nano-micelle in different medium.
The specific embodiment
Below in conjunction with specific embodiment, further illustrate the present invention.Should be understood that these embodiment are only not used in and limit the scope of the invention for the present invention is described.The experimental technique of unreceipted actual conditions in the following example, conventionally according to normal condition, or the condition of advising according to manufacturer.
embodiment 1
Precision takes TPGS respectively
10008g, pluronic F
1271g, ampelopsin 0.45g, be dissolved in appropriate methanol, by Rotary Evaporators vacuum, remove methanol at 37 ℃, in eggplant-shape bottle bottom and inwall form the uniform films of thin layer, the purified water that adds 50mL, aquation 30min in 37 ℃ of water-baths, sealing is placed in the about 6h of refrigerator, supersound process 10min, treat that thin film comes off completely, with the polycarbonate membrane difference filter 23 of 0.2 μ m, 0.1 μ m, obtain ampelopsin nano-micelle preparations successively, envelop rate is 80.1%.
embodiment 2
Precision takes TPGS respectively
10005g, pluronic F
1271g, ampelopsin 0.3g, be dissolved in appropriate methanol, by Rotary Evaporators vacuum, remove methanol at 37 ℃, in eggplant-shape bottle bottom and inwall form the uniform films of thin layer, the purified water that adds 50mL, aquation 30min in 37 ℃ of water-baths, sealing is placed in the about 6h of refrigerator, supersound process 10min, treat that thin film comes off completely, with the polycarbonate membrane difference filter 23 of 0.2 μ m, 0.1 μ m, obtain ampelopsin nano-micelle preparations successively, envelop rate is 74.9%.
embodiment 3
Precision takes TPGS respectively
10008g, pluronic F
1271g, ampelopsin 0.9g, be dissolved in appropriate methanol, by Rotary Evaporators vacuum, remove methanol at 37 ℃, in eggplant-shape bottle bottom and inwall form the uniform films of thin layer, the purified water that adds 50mL, aquation 30min in 37 ℃ of water-baths, sealing is placed in the about 6h of refrigerator, supersound process 10min, treat that thin film comes off completely, with the polycarbonate membrane difference filter 23 of 0.2 μ m, 0.1 μ m, obtain ampelopsin nano-micelle preparations successively, envelop rate is 70.7%.
embodiment 4
Precision takes TPGS respectively
10008g, pluronic F
1271g, ampelopsin 0.6g, be dissolved in appropriate methanol, by Rotary Evaporators vacuum, remove methanol at 37 ℃, in eggplant-shape bottle bottom and inwall form the uniform films of thin layer, the purified water that adds 50mL, aquation 30min in 37 ℃ of water-baths, sealing is placed in the about 6h of refrigerator, supersound process 10min, treat that thin film comes off completely, with the polycarbonate membrane difference filter 23 of 0.2 μ m, 0.1 μ m, obtain ampelopsin nano-micelle preparations successively, envelop rate is 72.7%.
embodiment 5
Use the method for preparing nano-micelle in above-described embodiment to make pastille nano-micelle, then by this pastille nano-micelle fill in ampoule bottle, through lyophilization, process, sealing, obtains ampelopsin nano-micelle lyophilized injectable powder.
embodiment 6 ampelopsin nano-micelle Morphological Characterizations
Get the ampelopsin nano-micelle that appropriate embodiment 1 makes, after dilution, with Nicomp 380/ZLS laser particle size and current potential, survey instrument and measure particle diameter and distribution and Zeta potential.Experimental result shows that the mean diameter of ampelopsin nano-micelle is at 22.8 ± 0.5nm, and polydispersity coefficient is all less than 0.2, shows that dispersion is good, and Zeta potential is-20.73mV.
Get the ampelopsin nano-micelle that embodiment 1 makes appropriate, use phosphotungstic acid negative staining, drip on the Electronic Speculum copper mesh of plated film, after drying, be placed in the form of electric Microscopic observation nanoparticle.As shown in Figure 1, visible nano-micelle is spherical, outward appearance rounding, and uniform particle diameter, size is consistent with the measurement result of laser particle analyzer.
embodiment 7 dissolubility are investigated
The ampelopsin nano-micelle lyophilized powder respectively embodiment 1 being made adds in certain water gaging, and in 25 ℃ of water bath with thermostatic control agitators, jolting is to dissolution equilibrium.Sampling is appropriate respectively, through 0.22 μ m microporous filter membrane, filters, and is placed in 10mL volumetric flask and adds methanol constant volume.By HPLC method, measure its peak area, by external standard counter point, difference calculated equilibrium dissolubility.Result demonstration, the ampelopsin dissolubility in ampelopsin nano-micelle of the present invention is by 0.4861 mgml of routine
-1be increased to 7.7444mgml
-1, increased by 16 times.
embodiment 8 ampelopsin nano-micelle extracorporeal releasing experiments
Essence is got bag filter that 2mL ampelopsin nano micellar solution that embodiment 1 makes is placed in treated mistake (in (8000-14000 dalton) respectively, after being tightened, puts into bag mouth the beaker of the different release medium (simulated gastric fluid, purified water, pH6.8 phosphate-buffered salt and pH7.4 cattle fetal blood are clear) that 200mL is housed, being placed in 37 ℃ of constant temperature oscillators shakes, regularly draw dialysis solution 1mL, simulated gastric fluid, purified water, phosphate-buffered salt and the cattle fetal blood of adding equivalent clear simultaneously.Adopt HPLC method to measure ampelopsin content, and calculate accumulative total release rate, its release profiles is shown in Fig. 2.As shown in the figure, 12h can more than 80% medicine of cumulative release in 4 kinds of different mediums for ampelopsin nano-micelle, and has certain slow-release capability.
embodiment 9 ampelopsin nano-micelle In Vitro Anti carcinoma of prostate activity experiments
1. ampelopsin nano-micelle In Vitro Anti carcinoma of prostate is active
1.1 experiment groupings
(1) the ampelopsin nano-micelle group that embodiment 1 makes is (containing ampelopsin, F127+TPGS1000; Medicine and total carrier are than being 1:20, and F127 and TPGS1000 ratio are 8:1): with ampelopsin content meter, establish respectively 25,50,100,150,200,250ug/ml Concentraton gradient.
(2) the naked medicine group of ampelopsin (only containing ampelopsin crude drug): establish 25,50,100,150,200,250ug/ml Concentraton gradient.
(4) blank group (not adding any medicine, cell normal growth): add isopyknic PBS or culture medium.
1.2 medicinal liquid preparations
(1) ampelopsin, with DMSO hydrotropy, is diluted to desired concn gradient (wherein DMSO concentration is not higher than 0.01%) by PBS or culture medium
(2) ampelopsin nano-micelle, directly with PBS preparation, is crossed the degerming of 0.1um filter membrane, with PBS or culture medium, is diluted to desired concn gradient.
1.3 mtt assay
The take the logarithm prostate gland cancer cell of trophophase, trypsinization counting, makes the single cell suspension of suitable concentration.96 orifice plates are around filled with PBS, and zone line is by the cell of every hole 180ul suspension inoculation suitable number.Cell attachment after cultivation 24h, adds the medicine of Concentraton gradient, and establishes blank, continues to cultivate 72h.After 72h, inhale and abandon culture fluid, add the MTT liquid of 5mg/ml, 20ul/ hole.Continue to hatch after 4h, carefully abandon supernatant, add DMSO dissolving crystallized, 150ul/ hole.Concussion 10min, upper microplate reader is measured OD in 570nm place.Be calculated as follows survival rate: survival rate (%)=(experimental group OD/ matched group OD) * 100%.
2 experimental results
The impact of 2.1 ampelopsin nano-micelles on prostate gland cancer cell PC-3 growth
The survival rate of PC-3 cell after table 1. variable concentrations ampelopsin and nano-micelle intervention thereof
Result shows, ampelopsin nano-micelle suppresses prostate gland cancer cell PC-3 successful and is better than ampelopsin raw material group, and both have significant difference (p<0.0l).
The impact of 2.2 ampelopsin nano-micelles on prostate gland cancer cell DU-145 growth
The survival rate of DU145 cell after table 2 variable concentrations ampelopsin and nano-micelle intervention thereof
Result shows, ampelopsin nano-micelle suppresses prostate gland cancer cell DU-145 successful and is better than ampelopsin raw material group, and both have significant difference (p<0.0l).
Although embodiment of the present invention are open as above, but it is not restricted to listed utilization in description and embodiment, it can be applied to various applicable the field of the invention completely, for those skilled in the art, can easily realize other modification, therefore do not deviating under the general concept that claim and equivalency range limit, the present invention is not limited to specific details and illustrates here and the legend of describing.
Claims (10)
1. an ampelopsin nano-micelle, is prepared from by carrier and ampelopsin; Described carrier is the mixture of pluronic F127 and polyethylene glycol 1000 vitamin E succinic acid ester;
The mass ratio that feeds intake of described ampelopsin and carrier is 1: 10 to 1: 30;
In described carrier, the mass ratio that feeds intake of pluronic F127 and polyethylene glycol 1000 vitamin E succinate is 1: 3 to 1: 10.
2. according to the ampelopsin nano-micelle described in claim 1, it is characterized in that: the mass ratio that feeds intake of described ampelopsin and carrier is 1: 20.
3. according to the ampelopsin nano-micelle described in claim 1, it is characterized in that:
In described carrier, the mass ratio that feeds intake of pluronic F127 and polyethylene glycol 1000 vitamin E succinate is 1: 8.
4. according to the ampelopsin nano-micelle described in claim 1 or 2 or 3, it is characterized in that: the mean diameter of described ampelopsin nano-micelle is 22.8 ± 0.5nm;
The polydispersity coefficient of the particle diameter of described ampelopsin nano-micelle is less than 0.2.
5. according to the ampelopsin nano-micelle described in claim 4, it is characterized in that: the Zeta potential of described ampelopsin nano-micelle is-20.73mV.
6. according to the ampelopsin nano-micelle described in claim 5, it is characterized in that: in described ampelopsin nano-micelle, the content of ampelopsin is 3.27 ± 0.12mg/ml.
7. the preparation method of the arbitrary described ampelopsin nano-micelle of claim 1-6, comprise the steps: the carrier of the ampelopsin of formula ratio and formula ratio to be placed in container, add wherein again methanol, ampelopsin and carrier are dissolved in methanol, by removing the step of methanol, make the mixture of ampelopsin and carrier on container inner wall, form thin film, in described container, add purified water again, formed thin film on container inner wall is carried out to hydration process, obtain hydration process product, obtain described ampelopsin nano-micelle.
8. according to the preparation method of the ampelopsin nano-micelle described in claim 7, it is characterized in that: the method for described hydration process is for being equipped with container jolting 30min at 37 ℃ of thin film and purified water.
9. the application of the arbitrary described ampelopsin nano-micelle of claim 1-6 in the medicine of preparation inhibition tumor.
10. according to the application described in claim 9, it is characterized in that: described inhibition tumor for suppress tumor propagation and/or
The survival of inhibition tumor cell;
And/or, the propagation that the propagation of described inhibition tumor is inhibition tumor cell and/or suppress that tumor sphere volume increases and/
Or promote disintegrating of tumor ball;
And/or described tumor is carcinoma of prostate; Described prostatic cell is prostate gland cancer cell PC-3, prostate gland cancer cell DU-145.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410249243.9A CN104042567A (en) | 2014-06-07 | 2014-06-07 | Ampelopsin nano-micelle and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410249243.9A CN104042567A (en) | 2014-06-07 | 2014-06-07 | Ampelopsin nano-micelle and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042567A true CN104042567A (en) | 2014-09-17 |
Family
ID=51496298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410249243.9A Pending CN104042567A (en) | 2014-06-07 | 2014-06-07 | Ampelopsin nano-micelle and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042567A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106750272A (en) * | 2016-12-05 | 2017-05-31 | 福建卫生职业技术学院 | A kind of water-soluble ampelopsin polymer |
| CN107019670A (en) * | 2017-04-18 | 2017-08-08 | 国家纳米科学中心 | A kind of nano-micelle pharmaceutical carrier based on vitamin e derivative, nano-micelle pharmaceutical composition and its preparation method and application |
| CN108014104A (en) * | 2018-01-22 | 2018-05-11 | 青岛科技大学 | A kind of Synergistic type dihydromyricetin soluble type compound and preparation method thereof |
| WO2019050969A1 (en) * | 2017-09-06 | 2019-03-14 | Prud'homme, Robert, K. | Dihydromyricetin nanoparticle formulations |
| CN109568297A (en) * | 2018-11-22 | 2019-04-05 | 福建中医药大学 | A kind of dihydromyricetin solid lipid nano granule and preparation method |
| US11103461B2 (en) | 2015-12-22 | 2021-08-31 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| US11554101B2 (en) | 2014-06-24 | 2023-01-17 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US11737981B2 (en) | 2017-09-12 | 2023-08-29 | The Trustees Of Princeton University | Cellulosic polymer nanoparticles and methods of forming them |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US12343324B2 (en) | 2018-11-14 | 2025-07-01 | The Trustees Of Princeton University | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
| US12357582B2 (en) | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
-
2014
- 2014-06-07 CN CN201410249243.9A patent/CN104042567A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11554101B2 (en) | 2014-06-24 | 2023-01-17 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| US11103461B2 (en) | 2015-12-22 | 2021-08-31 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| CN106750272A (en) * | 2016-12-05 | 2017-05-31 | 福建卫生职业技术学院 | A kind of water-soluble ampelopsin polymer |
| CN106750272B (en) * | 2016-12-05 | 2019-05-28 | 福建卫生职业技术学院 | A kind of water solubility ampelopsin polymer |
| CN107019670B (en) * | 2017-04-18 | 2020-06-16 | 国家纳米科学中心 | Vitamin E derivative-based nano-micelle drug carrier, nano-micelle drug composition, and preparation method and application thereof |
| CN107019670A (en) * | 2017-04-18 | 2017-08-08 | 国家纳米科学中心 | A kind of nano-micelle pharmaceutical carrier based on vitamin e derivative, nano-micelle pharmaceutical composition and its preparation method and application |
| WO2019050969A1 (en) * | 2017-09-06 | 2019-03-14 | Prud'homme, Robert, K. | Dihydromyricetin nanoparticle formulations |
| US11737981B2 (en) | 2017-09-12 | 2023-08-29 | The Trustees Of Princeton University | Cellulosic polymer nanoparticles and methods of forming them |
| US12357582B2 (en) | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
| CN108014104A (en) * | 2018-01-22 | 2018-05-11 | 青岛科技大学 | A kind of Synergistic type dihydromyricetin soluble type compound and preparation method thereof |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US12343324B2 (en) | 2018-11-14 | 2025-07-01 | The Trustees Of Princeton University | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
| CN109568297A (en) * | 2018-11-22 | 2019-04-05 | 福建中医药大学 | A kind of dihydromyricetin solid lipid nano granule and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104042567A (en) | Ampelopsin nano-micelle and application thereof | |
| CN102218027B (en) | Polymer micelle lyophilized agent encapsulating insoluble antitumor drug | |
| CN104434806B (en) | Lipid-mixed poly (lactic-co-glycolic acid) (PLGA) nanoparticle having high drug loading amount and active targeting effect | |
| CN103768024B (en) | Ginsenoside Rh2's albumin compound nano-particle and preparation method thereof | |
| CN101780037B (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| CN102379848A (en) | Paclitaxel immune nano liposome and preparation method and application thereof | |
| CN102558391B (en) | vitamin E succinate-chitosan graft and preparation method and application thereof | |
| CN103179967A (en) | Anti-tumor pharmaceutical composition | |
| CN107049944B (en) | Polymer micelle capable of realizing simultaneous administration of sorafenib and curcumin and preparation method thereof | |
| CN108245483A (en) | A kind of polymer nano micelle system for containing insoluble anti-tumor medicament | |
| Song et al. | Oligochitosan-pluronic 127 conjugate for delivery of honokiol | |
| US8765173B2 (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| CN104688722A (en) | Use of anhydroicaritin in preparation of myelosuppression prevention or treatment medicines | |
| CN107929262A (en) | Ethylenediamine cationized albumin anti-tumor nano grain and its preparation method and application | |
| AU2013377404A1 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| CN103315977A (en) | Folic acid modified quercetin lipid nano-capsule preparation and preparation method thereof | |
| CN106420618A (en) | Preparation method for Anti-CA IX modified norcantharidin micelle nanoparticle | |
| CN103356492A (en) | Tripterine pharmaceutical composition using albumin as pharmaceutical carrier | |
| CN107137350A (en) | A kind of taxol polymer micelle and preparation method thereof | |
| CN115252551A (en) | Microemulsion and freeze-dried powder for paclitaxel injection and preparation method thereof | |
| CN104086531B (en) | A kind of Esomeprazole sodium compound and its pharmaceutical composition | |
| CN109172520A (en) | A kind of taxane derivatives TM-2 micella injection and the preparation method and application thereof | |
| CN103735555B (en) | Cucurbitacin medicinal composition and pharmaceutical application thereof | |
| CN104784109B (en) | The temperature sensitive sustained release pharmaceutical composition of taxone | |
| CN107854430A (en) | A kind of paclitaxel oral nano suspension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140917 |
|
| WD01 | Invention patent application deemed withdrawn after publication |